Here, the expression of PTPN3 was observed to be substantially increased in both cisplatin and doxorubicin resistant ovarian cancer cells through the genomic analysis of cisplatin and doxorubicin resistant cells compared with the parental ovarian cancer cells. This evidence concerns the gene PTPN3 and ovarian cancer.